Landos Biopharma To Present New Data On NX-13 From Phase 1B Trial In Ulcerative Colitis At United European Gastroenterology Week 2023 Congress
Portfolio Pulse from Benzinga Newsdesk
Landos Biopharma will present new data on NX-13 from its Phase 1B trial in Ulcerative Colitis at the United European Gastroenterology Week 2023 Congress. The drug demonstrated rapid symptomatic relief and improvement in multiple biomarkers. The NEXUS Phase 2 Clinical Trial is ongoing with top-line readout expected in Q4 2024.
September 19, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Landos Biopharma's NX-13 shows promising results in Phase 1B trial for Ulcerative Colitis. Phase 2 trial is ongoing with results expected in Q4 2024.
The positive results from the Phase 1B trial of NX-13 and the ongoing Phase 2 trial could potentially boost investor confidence in Landos Biopharma, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100